archived version — not current
This is a permanent, read-only archive of this profile's public content as it existed on 2026-09-23. It does not reflect the current, live profile. View the current profile.
Snapshot captured 2026-09-23 — Published content materially edited
Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis and related metabolic outcomes. Liver histology, noninvasive markers, weight, and cardiovascular risk factors are distinct endpoints.
WPF’s atlas includes reports and abstracts from the phase 2b IMPACT study and a meta-analysis of randomized trials. Conference abstracts and top-line reports can flag emerging results, but require comparison with complete methods and peer-reviewed outcome data before firm conclusions.
This Directory entry has no published source-linked citations or jurisdiction-specific regulatory records. A change in a surrogate marker or exploratory analysis does not by itself establish clinical benefit, durability, or an approved indication.
Content hash: fd8015cca35b41b05798846f68a7d998e137ffb8720fa7c8fc54afb47d782468